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Abstract
Background: Internationally recognised evidence-based guidelines recommend appropriate triage of patients with
stroke in emergency departments (EDs), administration of tissue plasminogen activator (tPA), and proactive management
of fever, hyperglycaemia and swallowing before prompt transfer to a stroke unit to maximise outcomes. We aim to
evaluate the effectiveness in EDs of a theory-informed, nurse-initiated, intervention to improve multidisciplinary triage,
treatment and transfer (T3) of patients with acute stroke to improve 90-day death and dependency. Organisational and
contextual factors associated with intervention uptake also will be evaluated.
Methods: This prospective, multicentre, parallel group, cluster randomised trial with blinded outcome assessment will
be conducted in EDs of hospitals with stroke units in three Australian states and one territory. EDs will be randomised
1:1 within strata defined by state and tPA volume to receive either the T3 intervention or no additional support (control
EDs). Our T3 intervention comprises an evidence-based care bundle targeting: (1) triage: routine assignment of patients
with suspected stroke to Australian Triage Scale category 1 or 2; (2) treatment: screening for tPA eligibility and
administration of tPA where applicable; instigation of protocols for management of fever, hyperglycaemia and
swallowing; and (3) transfer: prompt admission to the stroke unit. We will use implementation science behaviour
change methods informed by the Theoretical Domains Framework [1, 2] consisting of (i) workshops to determine
barriers and local solutions; (ii) mixed interactive and didactic education; (iii) local clinical opinion leaders;
and (iv) reminders in the form of email, telephone and site visits. Our primary outcome measure is 90 days
post-admission death or dependency (modified Rankin Scale >2). Secondary outcomes are health status (SF-36),
functional dependency (Barthel Index), quality of life (EQ-5D); and quality of care outcomes, namely, monitoring and
management practices for thrombolysis, fever, hyperglycaemia, swallowing and prompt transfer. Outcomes will be
assessed at the patient level. A separate process evaluation will examine contextual factors to successful intervention
uptake. At the time of publication, EDs have been randomised and the intervention is being implemented.
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Discussion: This theoretically informed intervention is aimed at addressing important gaps in care to maximise 90-day
health outcomes for patients with stroke.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12614000939695. Registered 2 September 2014.
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Background
International clinical guidelines recommend early man-
agement of stroke on arrival to the emergency depart-
ment (ED) in order to improve patient outcomes [3–5].
Key elements of stroke care applicable to EDs are ap-
propriate triage; treatment by administration of tissue
plasminogen activator (tPA) to eligible patients and
management of fever, hyperglycaemia and swallowing;
followed by prompt transfer to an acute stroke unit.
Data available at the time of our T3 (triage, treatment
and transfer) Trial commencement demonstrated vari-
able practices. With regard to triage, allocation of an
Australasian Triage Scale (ATS) category 1 (to be seen
immediately) or category 2 (to be seen within 10 min)
is recommended for patients presenting to EDs with
signs or symptoms of acute stroke [6]. However, these
targets are not always met; an analysis of Victorian am-
bulance data demonstrated that 30 % of patients with
stroke were not allocated an ATS category of 1 or 2 [7].
Inappropriate triage allocation resulting in delays in as-
sessment and diagnosis also may have a flow-on ad-
verse effect on provision of thrombolysis to patients
who may benefit and create delays in implementation
of other elements of evidence-based stroke care.
In terms of treatment, Australian data from the 2013
Stroke Foundation national acute audit found that only
45 % of patients with ischaemic stroke presenting to
hospital within 3 h of stroke were assessed for tPA eligi-
bility [8]. Only 7 % of eligible patients received tPA [8]
with pockets of excellence where rates from individual
sites were up to 21 % [9]. Less than optimal tPA rates
also have been reported internationally; 12 % in the UK
[10] and less than 5 % in the USA [11]. However, data
from Norway, where collaboration for pre-hospital, ED
and acute services is streamlined, demonstrate higher
rates (31 %) are achievable [12]. In relation to the man-
agement of fever, hyperglycaemia and swallowing in
Australia, pre-trial data from the 2013 Stroke Founda-
tion national acute audit showed that only 60 % of pa-
tients received temperature monitoring four times a day
during the first 72 h of admission, with only 36 % of
those with a fever (>37.5 °C) receiving paracetamol
within 1 h [8]. Less than a quarter (21 %) received four
times a day glucose monitoring in the first 72 h of ad-
mission, and only 25 % patients with hyperglycaemia
(blood glucose >10 mmol/L) received insulin within 1 h
[8]. Two thirds (66 %) of patients received a swallow-
ing screen or assessment within 24 h of admission [8],
and of concern, only 52 % received a swallow screen/
assessment prior to oral intake [8]. Our own Quality in
Acute Stroke Care (QASC) trial data from the inter-
vention group showed that 18 % of patients with stroke
were given oral fluid or food before screening and
37 % were given oral medications [13]. Similarly, at the
T3 Trial commencement, variable practices were re-
ported regarding prompt transfer from ED to stroke
units with ED length of stays ranging from a median of
7 h (maximum 20 h) [13] up to 11 h [14].
In summary, EDs must deliver time-critical, best-
practice clinical care to optimise outcomes for patients
with stroke. A specific challenge for EDs is the delivery
of optimal care for patients with stroke whilst managing
other patients with a range of illnesses and injuries of
varying degrees of clinical urgency. It is clear that EDs
need greater support to deliver evidence-based triage,
treatment and transfer for patients presenting with acute
stroke in order to improve patient outcomes. Building
on our previous trial results [15], we aim to rigorously
evaluate, using a cluster randomised controlled trial
design, the effectiveness of a theory-informed, nurse-
initiated, organisational intervention to improve multi-
disciplinary care for patients with acute stroke in EDs
measuring outcomes at 90 days.
Methods
Hypothesis
Patient outcomes and quality of care
Compared to patients who receive care in EDs rando-
mised to the control group, patients who receive care in
EDs randomised to receive the T3 intervention will have:
Patient primary outcome
1) 10 % decrease in the proportion of patients dead
or dependent 90 days post hospital admission
(dependency defined as modified Rankin Score
(mRS) ≥2)
Patient secondary outcome
2) 10 % increase in the proportion of patients with
improved functional dependency 90 days post
hospital admission (Barthel Index (BI) ≥95)
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3) 0.2 standard deviations higher mean SF-36 Mental
Component Score (MCS) and Physical Component
Score (PCS) 90 days post hospital admission
(3.5 units for MCS; 2.5 units for PCS)
Quality of care (in-hospital) secondary outcomes
4) 15 % increase in the proportion of patients triaged
to Australasian Triage Scale (ATS) category 1 or 2
5) 20 % increase in the proportion of patients receiving
assessment for tPA eligibility
6) 10 % increase in the proportion of patients with
temperature readings on admission and 4 hourly
whilst in ED
7) 10 % increase in the proportion of patients with a
formal venous blood glucose level (BGL) sent to
the laboratory on admission to ED
8) 10 % increase in the proportion of patients with
finger prick glucose readings on admission and at
least 6 hourly whilst in ED
9) 10 % increase in the proportion of patients who are
either ‘Nil by Mouth’ or receive a swallow screen
or assessment within 24 h of ED admission
10)10 % increase in the proportion of patients who
remained ‘Nil by Mouth’ until they received a
swallow screen or assessment
11)10 % increase in the patients who received a
swallow screen or assessment within 24 h of ED
admission
12)10 % decrease in the proportion of patients given
oral fluids or food prior to a swallow screen or a
swallow assessment
13)10 % decrease in the proportion of patients given
oral medications prior to a swallow screen or a
swallow assessment
14)10 % increase in the proportion of patients
getting to the stroke unit within 4 h of
presentation to the ED
Study design
A prospective, multicentre, parallel group, blinded, cluster
randomised controlled trial (CRCT) with blinded outcome
assessment will be undertaken. The unit of randomisation
will be EDs in order to minimise contamination as our
intervention is designed for delivery at the organisational
level addressing environmental or ‘systems’ impediments
to best-practice stroke care in EDs. Outcomes will be
assessed at the patient level.
Eligibility and recruitment
Emergency departments
EDs at hospitals in three Australian states (NSW, VIC,
QLD) and the Australian Capital Territory (ACT) with
pre-existing dedicated stroke units will be eligible to
participate. EDs at hospitals already participating in a
stroke cluster randomised trial testing a thrombolysis
intervention will be ineligible to participate to prevent
possible contamination to either trial. We will meet ED
Directors, ED Nurse Unit Managers (NUMs), ED Nurse
Educators and the relevant Director of Allied Health as
well as the Director of each hospital stroke unit and the
stroke unit co-ordinator (or equivalent), to explain the
aims of the trial. The ED Director will provide cluster
guardian consent for the ED to be involved.
Patients
Two patient cohorts will be recruited prospectively using
identical methods by Clinical Research Assistants at each
site. The first cohort will be recruited pre-intervention
from all hospitals to provide baseline observational data.
Data will be obtained from a consecutive sample of pa-
tients who are English-speaking, aged >18 years, have
been admitted to the stroke unit via ED with a clinical
diagnosis of ischaemic stroke or intracerebral haemor-
rhage and presented to hospital less than 48 h from
symptom onset. Patients presenting later than this are
unlikely to benefit from changes in clinical care and will
be excluded. Also excluded will be those requiring
palliative care only, with identified non-cerebrovascular
causes of acute focal neurological deficits (seizure,
hypoglycaemia, toxic or metabolic encephalopathies),
sub-arachnoid haemorrhage, and acute and chronic
subdural haemorrhage.
Demographic data (age, sex, stroke sub-type [scale ex-
plained below]) and stroke severity (scale explained
below) will be obtained for all eligible consenting pa-
tients and also for eligible non-consenting patients to as-
sess for selection bias. All eligible patients will be given
a patient information statement outlining the study pur-
pose, data collection and the 90-day follow-up process
and information on how to opt-out/withdraw from the
data collection. Patients in the post-intervention cohort
will consent using an ‘opt-out’ approach. Consenting
patients (or their friend/relative) will be asked to agree
to be contacted by the researchers at 90 days to
conduct a computer-assisted telephone interview (CATI)
and to access their medical records. Patients will be
approached in the stroke unit. Eligible patients missed
whilst an in-patient on the stroke unit will be mailed the
patient information statement. Patients may withdraw at
any time without providing a reason. Recruitment rates by
sites will be monitored by the Trial Manager (SD); no
incentives for recruitment will be provided.
Randomisation and allocation concealment
Hospitals will be randomised within strata defined by
state and a baseline tPA rate (<7.7 vs >7.7 %; 7.7 % is the
average annual rate based on the 2013 Stroke Founda-
tion clinical audit [8]) in a 1:1 ratio to either intervention
or control group. De-identified hospital and stratification
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details will be provided to a blinded statistician not
otherwise involved in the trial to perform the random-
isation using SAS Proc Plan and allocate EDs to their
groups. Group allocation will be concealed until pro-
vided to the Trial Manager (SD).
T3 intervention
Control group
EDs randomised to the control group will receive no
additional support from the T3 Trialists nor receive any
of the T3 Trial clinical protocols.
Intervention group
This organisational intervention will be implemented in
EDs and will target healthcare professional behaviour for
acute stroke management. The intervention is comprised
of two components: the T3 protocols and the T3 imple-
mentation strategy, both described below.
The T3 protocols
In line with clinical practice guidelines, we have
designed an evidence-based care bundle of clinical
protocols for triage, treatment and transfer following
acute stroke comprised of 12 clinical care elements
(the T3 protocols). Developed by clinical experts, the
T3 protocols will be delivered by nurses (i.e. nurse-
initiated).
In order to prevent contamination before trial com-
pletion, we outline below broad components of our
intervention, rather than provide details of each clinical
behaviour as these will be published with the final trial
results:
Triage
 Appropriate triage allocation by nurses for patients
with suspected acute stroke
Treatment
 Assessment for eligibility for tPA
 Administration of tPA to eligible patients
 Fever, Sugar, Swallowing (FeSS) management.
Whilst similar to those successfully used in the
QASC trial [15] conducted by the researchers,
updated versions of the FeSS clinical protocols,
where required, will be developed by a
multidisciplinary panel of experts
Transfer
 Prompt transfer of patients with stroke from ED to
a stroke unit
The T3 implementation strategy
Implementation intervention development
The science of implementation research is still evolving
[16] with an incomplete but emerging evidence base to
guide researchers and clinician leaders in the development
of implementation interventions designed to implement
practice change. The use of theoretical frameworks can
assist with the systematic development of interventions
for implementation trials [17, 18]. Acknowledging,
however, that ‘no framework can address the level of detail
required to determine what will or will not be an effective
intervention’ [17, pg 3], we also retained elements of our
previously successful implementation strategy used in
the QASC trial [15, 19] consisting of workshops to
determine barrier identification with local solutions;
use of mixed interactive and didactic education; and
use of local clinical opinion leaders and reminders
(email, telephone and site visits).
The Theoretical Domains Framework (TDF) [1, 2]
was chosen to further guide intervention design be-
cause we wished to comprehensively analyse the na-
ture of the behaviours we were seeking to change and
link them to specific behavior change techniques [17].
The TDF consists of 14 theoretical domains derived
from 33 behaviour change theories, developed using a
process of expert consensus with subsequent valid-
ation work [20]. It has been used elsewhere in health-
care settings to study implementation and more
specifically assist the development of implementation
interventions [21–23].
Implementation strategy
The T3 protocols will be implemented using a theor-
etically informed [1, 2] and evidence-based behaviour
change implementation strategy [15] consisting of
workshops to determine barrier identification with
local solutions [24]; use of mixed interactive and di-
dactic education [25, 26]; use of local clinical opinion
leaders (site clinical champions) [24]; reminders in
the form of posters in ED, lanyard cards with listing
the clinical care elements [27]; and sustained site
engagement using site visits, telephone and email as
described below:
 Multidisciplinary workshops for ED and stroke
unit clinicians (medical practitioners, nurses and
speech pathologists) and endocrine clinicians will
be conducted by investigator nurses (SM and SD)
with emergency, neurology and endocrine physician
investigator researchers in attendance. Two face-to-
face 60-min workshops will be held in the ED, 10
to 16 weeks apart with the same attendees. The first
will target identification of local barriers, solutions
and enablers to implementation of the T3 clinical
care elements and also to reinforce enhanced team
function. Any local adaptation to the clinical care
elements required will be identified a priori. After
the first workshop, site-specific action plans will be
developed and discussed at the second workshop.
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 Interactive and didactic education program for ED
and stroke unit clinicians will be conducted
explaining the intervention. A 15-min PowerPoint
presentation will be delivered by Project Manager
(SD) and T3 State Co-ordinators in one education
session to ED and stroke unit clinicians collectively.
The PowerPoint presentation and an 8-min video
featuring an
academic ED nurse (JC) explaining the 12 clinical
care elements and their rationales will be provided
to the site champions to deliver to any other
members of the ED team and for ongoing
education of new staff. T3 researchers will be
available for any additional education sessions
requested by individual sites if required.
 Local clinical opinion leaders (site clinical
champions) from both the ED and the stroke unit
identified at the first workshop (described above)
will drive clinical change locally.
 Reminders will be aimed at sustained engagement
of ED and stroke unit champions. This will consist
of posters placed in the ED by site champions and
lanyard cards listing the 12 clinical care elements.
 Sustained engagement of ED and stroke unit
champions to embed organisational linkages and
collaboration by the T3 state co-ordinators by
6-weekly site contact to discuss progress against
the action plans, alternating between site visits and
teleconferences; and follow-up of reactive telephone
calls and emails initiated by local site champions.
Our intervention is aimed at behaviour change at
both the individual clinician level and the organisa-
tional level.
Implementation fidelity
In order to maintain fidelity of our intervention delivery,
all workshop and education sessions will be facilitated
by one or more of the researchers (SM, SD, LC, VS); all
of whom will undergo training to promote consistency
in delivery methods and content. Workshops will be
audiotaped to enable data collection of barriers and en-
sure the development of accurate and relevant action
plans. A standardised PowerPoint presentation will en-
sure the didactic component of the education will be
consistently delivered.
Outcome measures
Ninety-day patient outcomes: telephone interview
(intervention outcomes)
Patients will be telephoned 90 days post-admission and
asked to complete a 30-min computer-assisted telephone
interview (see data collection procedure below) using pre-
viously validated and commonly used scales to measure:
 Death or dependency: modified Rankin Score
(mRS) of ≥2 (primary outcome). The mRs is
a 6-point scale where 0 = independent and
6 = dead [28].
 Functional dependency: Barthel Index (BI). The
BI measures patient performance in 10 activities
of daily life relating to self-care (feeding, grooming,
bathing, dressing, bowel/bladder care, toilet use)
and mobility (ambulation, transfers, stair
climbing) [29].
 Health status: Medical Outcomes Study Short Form
36 Health Survey Questionnaire (SF-36). The SF-36
includes a single ‘health transition rating’ and scores
eight health domains which are aggregated to form
the Physical Component Score (PCS) and the
Mental Component Score (MCS) [30].
 Health-related quality of life: EuroQol 5D (EQ-5D)
measures five dimensions of care: mobility,
self-care, usual activities, pain and discomfort,
and anxiety and depression, and will inform the
economic evaluation [30].
Clinical data and quality of care outcome
measures—retrospective medical record audits
(implementation outcomes)
The following clinical measures and patient characteris-
tics will be collected from patient medical records: age;
sex; pre-morbid mRS; length of hospital stay; time from
onset of symptoms to arrival in ED; stroke sub-type
using the Oxfordshire Community Stroke Project
(OCSP) Classification [31] (a four-item scale that classi-
fies strokes using explicit criteria as either lacunar in-
farcts, total anterior circulation infarcts, partial anterior
circulation infarcts or posterior circulation infarcts);
and stroke severity using the National Institutes of
Health Stroke Scale (NIHSS) score [32] (ranges from 0
to 42, with higher values reflecting more severe cerebral
infarcts); diabetes status; and stroke risk factors (past
history of stroke/TIA, hypertension, hyperlipidaemia,
smoking status).
We also will collect data to measure the quality of care
outcomes and implementation efficacy as follows: ATS
category allocation; time to first seen by an ED doctor;
assessment of eligibility for tPA and result (eligible/not
eligible); receipt of tPA; all temperature and blood
glucose measurement times and values whilst in ED and
in stroke unit up to 72 h following admission; paraceta-
mol and insulin administration and mode of delivery;
swallow screening data (whether a swallow screen was
performed in ED, and before patients were given food,
drink or medications); whether those who fail the screen
were reviewed by a speech pathologist; and length of
time spent in the ED and the stroke unit.
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Data collection process, data entry and data storage
Patients will be contacted by telephone 90 days
following admission by the computer-assisted telephone
interview (CATI) research assistant (RA) blind to the
study design and group allocation. The CATI RA will
undergo training in telephone administration of the
study measures and mRS assessment certification and
will enter all 90-day data into the database. One week
prior to the CATI, a reminder letter will be mailed to
patients as a response-aiding strategy. This also enables
relatives of any deceased patients to contact us to inform
us of their family member’s demise. Where patients’
level of disability or dysphasia precludes them from
talking on the telephone, a relative or carer will be
invited to respond on behalf of the patient as a proxy.
Independent research assistants not otherwise in-
volved in the study, blind to the group allocation and
study design, will be trained to undertake the retro-
spective medical record audits and data entry. Interrater
reliability will be established by independent double-
auditing 10 % of randomly selected records, based on
computer-generated random numbers, with a minimum
of five records per site for the pre- and post-intervention
audit, respectively. Agreement between auditors will be
assessed using Kappa statistic [33].
Implementation of the intervention
After a 3-month bedding down period [15] to allow our
intervention to lead to behaviour change that has be-
come routine care, the second ‘post-intervention’ cohort
of patients will be recruited prospectively from all hospi-
tals to provide post-intervention outcome data using
similar tools and methods to those used to collect pre-
intervention data.
Blinding
Patients will be blinded to the trial aim and group
allocation. Research assistants collecting the 90-day
outcome measures and those collecting the medical
record audit data will be masked to trial aims, design
and group allocation; the trial statisticians will be
blinded to the group allocation. Clinicians delivering
the intervention in EDs and clinicians in their re-
spective stroke units will not be blinded to the group
allocation.
Sample size
We plan to recruit 1160 patients following implementa-
tion of the intervention in our post-intervention cohort,
anticipating a 10 % loss to follow-up [15]. Our trial will
have 80 % power at a 5 % significance level with the
following assumptions based on our previous QASC
trial: 50 % of patients in the usual care group will have
mRS ≥2, 60 % will have Barthel Index ≥95, standard
deviations for MCS and PCS of 11 and a design effect of
1.4. This will allow detection of a difference between
intervention and control groups at 90 days post-
admission of 10 % for mRS ≥2 (primary outcome); 10 %
for Barthel Index (BI)) ≥95 (secondary outcome 1); and
0.2 standard deviations (approximately 2.5 units) for
SF-36 Physical Component Score (PCS) (secondary
outcome 2) and SF-36 Mental Component Score
([MCS) (secondary outcome 3). Similarly, we will be
able to detect a difference in the process of care out-
comes between intervention and control groups of at
least 10 %.
Statistical methods
An intention-to-treat analysis will be undertaken using
the Stata statistical package. Demographic and clinical
characteristics will be presented by group.
Analysis of outcomes will involve regression (logistic
or linear as appropriate) with adjustment for baseline
values of the outcome and correlation of outcomes
within hospitals. We will undertake unadjusted analyses,
as well as analyses which adjust for baseline covariates.
Primary analysis will be a complete case analysis with
sensitivity analyses using multiple imputations to ac-
count for missing data, ensuring that all patients are in-
cluded in an intention-to-treat analysis.
Adherence to specific protocol analysis will be under-
taken using the 12 clinical care elements or variations
agreed a priori with each individual hospital. A planned
economic evaluation also will be conducted for which a
separate protocol will be published. No interim analyses
are planned.
Examination of contextual factors influencing knowledge
transfer: a process evaluation
At the conclusion of the T3 Trial, we will conduct
focus groups and semi-structured interviews to exam-
ine the contributing organisational, contextual and
structural factors that may explain successful uptake
of the T3 intervention.
All data will be stored, managed and archived in ac-
cordance with National Health and Medical Research
Council requirements. Data transferred to third parties
will be password-protected. We will archive the final
trial data set in a data repository. Only de-identified data
will be analysed. Data transcripts from focus groups and
interviews will not be identified by participant name, but
an identification number will link a participant’s name in
a file which will be stored separately from the tran-
scripts. No identified data will be published or released.
All study material will be disposed of in a confidential
manner by shredding all interviews transcripts and
erasing all audiotapes and computer files. The following
authors have access to the full data sets SM, SD and
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EM; CDE and PM will have access to the de-identified
data sets. Manuscripts will be prepared for peer-
reviewed publication to communicate trial results re-
gardless of the magnitude or direction of effect.
At time of publication, EDs have been randomised
and patients are being recruited, with the first
patient recruited in July 2015 (Fig. 1). Further details
about the T3 Trial enrolment, interventions and
assessments are shown in the SPIRIT flow diagram
(Additional file 1).
Discussion
There are approximately 60,000 new or recurrent
strokes annually in Australia [34]. Cost of subsequent
lifetime care has been estimated to exceed $2 billion
[35]. Whilst extensive research has confirmed the
importance of in-patient stroke unit care as a posi-
tive predictor of survival and recovery [36], it is
expected that even better results will be realised with
focused evidence-based stroke care in EDs before
transfer to a dedicated stroke unit. Acknowledging
the complexity of the ED environment [37], our trial
uses an evidence-based, multifaceted and multidiscip-
linary approach to address key elements of ED stroke
care with demonstrated evidence-practice gaps.
We have built on our previously successful QASC
trial results by replicating and enhancing our proven
intervention using a theoretical framework, the
Theoretical Domains Framework to guide the refine-
ment of our T3 intervention aiming to maximise
intervention uptake by clinicians. A strength of our
trial is that we are undertaking a process evaluation
alongside our CRCT [38].
Stroke is common and costs large if not treated
according to evidence-based guidelines during all
phases of hospital admission. To improve the ‘whole
pathway’ in stroke, care between EDs and stroke units
must be more collaborative and evidence-based.
Nurses are well placed to lead this collaborative in-
patient care [39]. Community interest in quality of
care, healthcare efficiency and post-discharge out-
comes is increasing [40]. We believe the study’s
rigour, timeliness and novelty will also set new bench-
marks for hospital-based implementation research
internationally.
Fig. 1 CONSORT flow diagram of the progress through the T3 Trial
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